Adeniyi Odugbesan, MD
Endocrinology, Diabetes & Metabolism · Lawrenceville, GANPI 1528175601
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $536,393 of the $635,656 with a category attached, or 84.4%. 60 manufacturers reported payments, led by Novo Nordisk at 45.6% of the total. Reporting peaked in 2019 at $187,866 and has fallen 53.5% since, to $87,423 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,331 payments — averaging $477.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$290K
- Johnson & Johnson$63K
- Merck$58K
- Lilly USA, LLC$54K
- AstraZeneca$44K
- Amgen$37K
- plus $90K from 54 others
Across 1,821 payments — averaging $643.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$555K
- Novo Nordisk AS$346K
- Siemens Medical Solutions USA, Inc.$108K
- Pfizer$71K
- Sanofi US Services Inc.$28K
- Eli Lilly$22K
- plus $43K from 5 others
What the payments were for
- Consulting fees$23,2304%
- Speaking & faculty fees$536,39384%
- Travel & lodging$47,9068%
- Food & beverage$28,0474%
- Education$800%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$174,311
- RYBELSUS$84,023
- JARDIANCE$73,049
- INVOKANA$61,982
- STEGLATRO$52,417
- FARXIGA$42,901
- EVENITY$17,756
- Prolia$17,343
- Kerendia$13,861
- FreeStyle Libre Pro$12,923
- CYCLOSET$6,147
- Vascepa$5,235
- TOUJEO$3,171
- Korlym$2,307
- FREESTYLE LIBRE 3$1,372
- Tresiba$982
- t:slim X2 Insulin Pump with Control-IQ$466
- iLet Bionic Pancreas$430
- Omnipod$421
- TEPEZZA$377
How this compares
$635,656 in reported general payments places this provider in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 292 | $466,690 |
| MounjaroTirzepatide | 97 | $131,524 |
| FarxigaDapagliflozin Propanediol | 109 | $129,627 |
| TrulicityDulaglutide | 80 | $117,402 |
| JardianceEmpagliflozin | 91 | $110,660 |
| JanuviaSitagliptin Phosphate | 47 | $55,436 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $54,656 |
| Tresiba Flextouch U-200Insulin Degludec | 21 | $47,784 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $45,940 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 29 | $34,539 |
| RybelsusSemaglutide | 19 | $31,206 |
| Novolog FlexpenInsulin Aspart | 85 | $29,959 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 26 | $29,546 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 16 | $25,042 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 146 | $21,981 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $289,660 | $508,489338 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $53,817 | $257,438205 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta | $26,844 | $166,537135 claims |
| AstraZenecaFarxiga | $44,307 | $129,627109 claims |
| MerckJanuvia, Janumet Xr | $58,125 | $84,98273 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $11,855 | $21,42812 claims |
| AbbVieSynthroid | $230 | $9,42685 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $194 | $5,671533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Lawrenceville
- David ShoreLawrenceville$83K
- David ArkinLawrenceville$15K
- Aparna MahakalaLawrenceville$12K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.